Auris Medical Holding AG (NASDAQ:EARS) shares were down 6.9% during mid-day trading on Tuesday . The company traded as low as $0.26 and last traded at $0.27. Approximately 1,297,221 shares changed hands during trading, an increase of 26% from the average daily volume of 1,032,271 shares. The stock had previously closed at $0.29.
Separately, ValuEngine upgraded shares of Auris Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04. The company has a market capitalization of $12.44, a PE ratio of -0.40 and a beta of 0.11.
A hedge fund recently bought a new stake in Auris Medical stock. Virtu KCG Holdings LLC purchased a new stake in Auris Medical Holding AG (NASDAQ:EARS) during the second quarter, according to its most recent filing with the SEC. The firm purchased 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical at the end of the most recent reporting period. 19.11% of the stock is owned by institutional investors.
Auris Medical Company Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.